-
On December 1-2, 2025, WHO issued its first guidelines recommending long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government finalized deals lowering prices for these drugs under Medicare and Medicaid, expanding coverage to more patients. Despite benefits, studies show weight and health gains reverse if treatment stops, highlighting need for ongoing care.
-
The NHS has approved the use of vutrisiran, a treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), following NICE guidance. The drug, made by Alnylam, reduces harmful protein deposits in the heart and will be available for eligible patients in England and Wales. This marks a significant step in managing a progressive, often undiagnosed condition.
-
Multiple stories highlight critical health issues: a UK girl with aplastic anaemia seeks a stem cell donor, a UK girl with Type 1 diabetes dies from neglect, and a US girl with Hunter syndrome benefits from experimental gene therapy. Investigations reveal neglect, malpractice, and advances in treatment.
-
Novo Nordisk's trials of the drug Rybelsus, containing semaglutide, did not meet their primary goal of delaying cognitive decline in early Alzheimer's patients. While some biological processes improved, the studies showed no effect on cognition. Shares fell sharply amid disappointment, though the drug remains beneficial for diabetes and obesity.